Slide 1: Q2FY25 Investor Presentation
~ Mankind/I/JI. J'~$jle, Q2FY25 05 November 2024
Slide 2: Index
~ Mankind/1//J,,,, J'~.t',# Index 03 Additional Information • Business Updates - H1FY25 • ESG • Mankind Pharma at a Glance • Key Milestones & Key Strengths 01 Financial Performance • Strategy Going Ahead • Key Financials – Q2 FY25 • Expansion in Specialty and Super Specialty • P & L Highlights – Q2
Slide 3: Financial Performance
~ Mankind/I/JI. J'~$jle, i I ■ I rf rm n
Slide 4: Q2 FY25 - Key Financial Snapshot
Q2 FY25 - Key Financial Snapshot ~ Mankind/I/JI. J'~$jle, Financials / Margins Growth Capital Efficiency 3,077 13.6% 35.3% Revenue (INR Cr) YoY Growth ROCE1 853 / 27.7% 24.3% 30.5% EBITDA (INR Cr) / Margin YoY Growth ROE1 Mr. Rajeev Juneja 659 / 21.4% 28.9% Vice Chairman & Managing Director PAT (INR
Slide 5: Q2 & H1 FY25 - P&L Highlights
Q2 & H1 FY25 - P&L Highlights ~ Mankind/I/JI,,,, J'~$jle, YoY QoQ YoY INR Crore Q2FY25 Q2FY24 Q1FY25 H1FY25 H1FY24 Growth Growth Growth Revenue from Operations 3,077 2,708 13.6% 2,893 6.3% 5,970 5,287 12.9% (A=B+C) Domestic Business (B) i. Domestic Business (ex CH) 2,796 2,564 2,529 2,336 10.5% 9.7%
Slide 6: Key Financial Metrics
Key Financial Metrics ~ Mankind/I/JI. J'~$jle, ROE* ROCE* Net Cash (INR crore) Dip on account of acquisition 4,255 Dip on account 31% of acquisition 29% 3,260 24% 34% 35% 23% 28% 2,159 25% 1,366 Mar31, Mar31, Sept30, Sept30, Mar31, Mar31, Sept30, Sept30, Mar31, Mar31, Sept30, Sept30, 2023 2024 2023
Slide 7: Business Updates – Q2 FY25
• Mankind//JJJ,,. J~.t'j!e, ■ I t
Slide 8: Domestic Business Performance
Domestic Business Performance ~ Mankind/I/JI. J'~$jle, Strong Growth in Domestic Revenue* INR Crore 9,522 8,453 7,595 11% 2,529 2,796 FY22 FY23 FY24 Q2FY24 Q2FY25 Secondary sales growth of 8.6% vs 8.0% IPM growth (1.1x to IPM) supported by strong outperformance of 3.4x volume growth to IPM (1.3%
Slide 9: Increasing Share of Chronic Segment
Increasing Share of Chronic Segment ~ Mankind/I/JI. J'~$jle, Increased chronic share by 119bps in last 12 months Consistent focus to increase chronic contribution 1.3x outperformance to IPM chronic in Q2FY25 37 38 38 36 3.0% 37 38 2.5% - - - - - 1.5x 13 19 1.3x 14 1.4x 14 1.1x 1.3x 35 12 11 10 34 34
Slide 10: Q2FY25 – Therapywise Performance
Q2FY25 – Therapywise Performance ~ Mankind/I/JI. J'~$jle, High Ranks across Acute and Chronic Areas Q2FY25 - Sales Mix representing Diversified Therapy Presence FY 20-24 CAGR 3% Rank in CVM Key Therapy Areas 8% (Q2FY25) 16% Mankind IPM 5% • Anti-Infectives • Cardiovascular Chronic therapies Cardiova
Slide 11: Building Consumer Healthcare Franchise
Building Consumer Healthcare Franchise ~ Mankind/I/JI. J'~$jle, Consumer Healthcare Segment Revenue (INR Crore) EBITDA % 19.9% 19.2% 19.1% 2% 692 706 589 20% 193 232 FY22 FY23 FY24 Q2FY24 Q2FY25 Strong revenue growth of 20% YoY1 in Q2FY25 propelled by steady growth in key brands like Manforce, Gas
Slide 12: Strong Corporate Identity Complements Brand Recall
Strong Corporate Identity Complements Brand Recall… ~ Mankind/I/JI. J'~$jle, Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 MAN~ Condom Brand Kartik Aaryan .,._ Sunny Leone Market Share – 28% Amitabh
Slide 13: Exports Business Update
Exports Business Update ~ Mankind/I/JI. J'~$jle, Revenue from Exports (INR Crore) 813 296 281 187 179 FY22 FY23 FY24 Q2FY24 Q2FY25 Revenue growth of 57% YoY driven by increase in our base business supported by new launches in last 12-24 months During the quarter, we have launched 1 new product i
Slide 14: Additional Information
ig Mankindlll> Vy) Additional Information
Slide 15: H1FY25 Business Updates
H1FY25 Business Updates ~ Mankind/I/JI. Strong Growth in Domestic Revenue Consumer Healthcare Segment Revenue from Exports J'~$jle, (INR crore) Revenue (INR crore) (INR crore) 10% 59% 5,430 540 4,948 438 401 339 H1FY24 H1FY25 H1FY24 H1FY25 H1FY24 H1FY25 1.3x outperformance to IPM chronic 2x outperfo
Slide 16: ESG: Organization Focus on Sustainable Growth
ESG : Organization Focus on Sustainable Growth# (H1’25) ~ Mankind/I/JI. J'~$jle, Key Key Key Adoption of Highlights Initiatives Priorities Technologies Zero Reportable Lost Time accidents across all • 65.5% Hazardous waste disposal for • 9,308 MT of EPR target of • CO2 emission reduction to • Comple
Slide 17: ESG Goals
ESG Goals ~ Mankind/I/JI,,,, J'~$jle, Environment* r r Hazardous Waste - 70% for Implementation of Wild life co-processing and 30% for • • • Conservation plan for 2 no's Plastic Neutral in FY24** landfilling by 2027 (Base of Schedule-1 species in year FY21) Sotanala area L r e Carbon neutral by 2030
Slide 18: Mankind Pharma at a Glance
Mankind Pharma at a Glance ~ Mankind/I/JI. J'~$jle, #1 Youngest #4 4 Rank in Prescriptions over Rank by value in Consumer Healthcare brands in Top 5 of the IPM* Market the last seven years* IPM* ranked #1 in their categories* Leadership INR 10,335 Crore 92% 23 16,000+ Brand families* worth FY24 Reve
Slide 19: Mankind Pharma - Key Milestones
Mankind Pharma - Key Milestones ~ Mankind/I/JI. J'~$jle, Sustained Improvement in Domestic Formulations Market Share and Ranking Market Share 4th Rank 8th Rank 4.1% 4.4% 3.3% -· 1995 2004 2007-10 2012 • 2015 • 2018-19 • 2020 • 2021 2022 • • 2023 • 2024 ~ I ••• 0 I MAN~ I fl ~ -~ I ~~ ~ <, •• r!t.l I
Slide 20: Key Strengths
Key Strengths ~ Mankind/I/JI. J'~$jle, India revenues contribute 92% of total revenues in FY24 Focus on Focus on Net cash of INR 3,260 Cr** with consistent CFO/ domestic Strong domestic EBITDA ratio in excess of 80% during FY24 business Volume- balance sheet business with best in growth driven Consi
Slide 21: Strategy Going Ahead
Strategy Going Ahead ~ Mankind/I/JI,,,, J'~$jle, Increase the value of prescriptions in existing markets by expanding market coverage; CVM moved from 62% in FY21 to 69% in FY24* Increasing share of chronic segment by growing presence in existing therapies (Diabetes - Insulin Glargine, Respiratory –
Slide 22: Consistently Expanding to Specialty and Super Specialty
Consistently Expanding to Specialty and Super Specialty ~ Mankind/I/JI. J'~$jle, Mankind Pharma Domestic From mass market to consumer to specialty chronic + Mass Market + (Acute/ Chronic / Semi Chronic) r--------------------------- Specialty Chronic (Cardio / Diabeto / CNS) Consumer Healthcare (OTC)
Slide 23: Consistently Expanding Our Portfolio Towards Specialty Products
Consistently Expanding Our Portfolio Towards Specialty Products ~ Mankind/I/JI. J'~$jle, Reference Brand Launched Market 5 ., Therapy Area Indication Market Size Rationale (Year) (INR Cr) Year CAGR • Neptaz – In-licensed from Novartis. Strong Revenue and Volume Neptaz # (2023) Heart Failure 6261 21%
Slide 24: Financials - Steady Growth Trajectory
Financials - Steady Growth Trajectory ~ Mankind/I/JI,,,, J'~$jle, Revenue (INR Cr) Strong Growth in Domestic Revenue Revenue from Exports (INR crore) --0 15% CAGR 8,749 10,335 -----0 13% CAGR 8,453 9,522 0 81% CAGR 813 7,782 7,595 5,865 6,214 6,028 5,789 296 - - 186 187 76 FY20 FY21 FY22 FY23 FY24 F
Slide 25: Key Performance Highlights
Key Performance Highlights ~ Mankind/I/JI. J'~$jle, Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 FY24 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 8.5 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 4.4 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 4 CVM share in t
Slide 26: Shareholding Pattern
Shareholding Pattern ~ Mankind/I/JI,,,, J'~$jle, BSE Ticker 543904 1.6% 3.1% 7.0% NSE Symbol MANKIND 13.5% Market Cap. (INR Crore)* 1,00,988 % Free Float 25.1 Free Float Market Cap. (INR Crore) 25,348 74.9% Shares Outstanding (Crore) 40.06 Industry Pharmaceuticals ■ Promoters ■ FPI & Bodies Corporat
Slide 27: Annexures
□ Annexures • ROE = (Profit for the year) / (average total equity less cash) • Mankind/II/JI,,> J'~-!'i/i o Profit excludes interest income and gain on current investments measured at FVTPL • Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash) o Profit excludes
Slide 28: Safe Harbour Statement
□ Safe Harbour Statement • Mankind/II/JI,,> J'~-!'i/i The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”
Slide 29: Q2 & H1 FY25 Earnings Call Details
Q2 & H1 FY25 Earnings Call Details Date 05 November, 2024 Time 06:00 PM IST Dial – In Details Universal Access Numbers +91 22 6280 1120 / +91 22 7115 8003 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=4789128&linkSecurityString=1fd9251b90 29
Slide 30: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Abhishek Agarwal Investor Relations – 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com